备注: R/R: Relapsed/Refractory复发/难治; ALL: Acute Lymphoblastic Leukemia急性淋巴细胞白血病; MM: Multiple Myeloma多发性骨髓瘤; NHL: Non-Hodgkin's Lymphoma非霍奇金淋巴瘤; AML: Acute Myeloid Leukemia急性髓系白血病 1 单靶点CAR-T疗法与双靶点...
该项目是探讨预防性阿那白滞素在靶向CD19的CAR-T细胞治疗复发难治大B细胞淋巴瘤和套细胞淋巴瘤患者中的疗效的2期临床试验。初步结果表明,在接受靶向CD19的CAR-T细胞治疗的淋巴瘤患者中,预防性阿那白滞素可降低ICANS发生率。 靶向C...
4. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy 译：动态监测循环肿瘤DNA 揭示接受 CAR T 细胞治疗的复发或难治性大 B 细胞淋巴瘤患者的结果和基因组变化 作者列表:Zou H;L...
Cellular therapy increases survival in recurring B-cell lymphoma: Clinical trialhttps://medicalxpress.com/news/2024-02-cellular-therapy-survival-recurring-cell.html版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023.https://doi.org/10.1038/s41591-023-02404-6
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...
Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
想寻求CAR-T疗法帮助或参与临床试验获得天价疗法免费治疗机会的患者，可将治疗经历、近期影像学及病理检查结果等，提交至医学部，进行初步评估!参考资料 [1]Neelapu S S,et al.Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial[J]. Nature ...
et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. O网页链接[2].Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...